We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 31, 2020

T-DM1 Plus Non-Pegylated Liposomal Doxorubicin in HER2+ Metastatic Breast Cancer

Cancers

 

Additional Info

Cancers
Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
Cancers (Basel) 2020 Nov 25;[EPub Ahead of Print], E López-Miranda, JM Pérez-García, S Di Cosimo, E Brain, M Ravnik, S Escrivá-de-Romaní, M Vidal, J Gligorov, S Borštnar, L Calabuig, M Sampayo-Cordero, A Malfettone, A Llombart-Cussac, TM Suter, J Cortés

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading